HK1043590A1 - 毒蕈碱性拮抗物 - Google Patents

毒蕈碱性拮抗物 Download PDF

Info

Publication number
HK1043590A1
HK1043590A1 HK02105117.5A HK02105117A HK1043590A1 HK 1043590 A1 HK1043590 A1 HK 1043590A1 HK 02105117 A HK02105117 A HK 02105117A HK 1043590 A1 HK1043590 A1 HK 1043590A1
Authority
HK
Hong Kong
Prior art keywords
muscarinic antagonists
alkoxy
halogen
alkyl
substituents selected
Prior art date
Application number
HK02105117.5A
Other languages
English (en)
Chinese (zh)
Inventor
W. Clader John
A. Kozlowski Joseph
W. Mccombie Stuart
W. Miller Michael
F. Vice Susan
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK1043590A1 publication Critical patent/HK1043590A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK02105117.5A 1999-09-22 2000-07-05 毒蕈碱性拮抗物 HK1043590A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22
US19990401391 1999-09-22
PCT/US2000/018358 WO2001021590A1 (en) 1999-09-22 2000-07-05 Muscarinic antagonists

Publications (1)

Publication Number Publication Date
HK1043590A1 true HK1043590A1 (zh) 2002-09-20

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105117.5A HK1043590A1 (zh) 1999-09-22 2000-07-05 毒蕈碱性拮抗物

Country Status (14)

Country Link
EP (1) EP1214299B1 (https=)
JP (1) JP2003509494A (https=)
CN (1) CN1167682C (https=)
AR (1) AR025459A1 (https=)
AT (1) ATE264301T1 (https=)
AU (1) AU5786300A (https=)
CA (1) CA2384018C (https=)
CO (1) CO5180624A1 (https=)
DE (1) DE60009931T2 (https=)
ES (1) ES2215055T3 (https=)
HK (1) HK1043590A1 (https=)
MX (1) MXPA02003136A (https=)
PE (1) PE20010649A1 (https=)
WO (1) WO2001021590A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
DE60213629T2 (de) * 2001-10-10 2007-10-18 Schering Corp. Piperidinverbindungen als muscarinantagonisten
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3371164B1 (en) 2015-11-06 2022-03-16 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
EP4069367B1 (en) 2019-12-06 2024-05-15 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
AU756484B2 (en) * 1998-06-30 2003-01-16 Schering Corporation Muscarinic antagonists

Also Published As

Publication number Publication date
ES2215055T3 (es) 2004-10-01
CN1374949A (zh) 2002-10-16
AU5786300A (en) 2001-04-24
WO2001021590A1 (en) 2001-03-29
EP1214299B1 (en) 2004-04-14
AR025459A1 (es) 2002-11-27
DE60009931D1 (de) 2004-05-19
CA2384018C (en) 2010-01-12
CN1167682C (zh) 2004-09-22
CO5180624A1 (es) 2002-07-30
CA2384018A1 (en) 2001-03-29
EP1214299A1 (en) 2002-06-19
MXPA02003136A (es) 2002-09-30
ATE264301T1 (de) 2004-04-15
PE20010649A1 (es) 2001-06-19
JP2003509494A (ja) 2003-03-11
DE60009931T2 (de) 2005-04-07

Similar Documents

Publication Publication Date Title
WO2002051808A3 (en) Muscarinic antagonists
CA2341739A1 (en) Quinolin-2-one derivatives useful as anticancer agents
GB9401460D0 (en) Compositions of matter
AU563683B2 (en) Substituted acyl derivative of 1,2,3,4-tetrahydroiso- quinoline-3-carboxylic acid
CA2262502A1 (en) 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
DE69030631D1 (de) Biphenylmethanderivate, ihre Anwendung und sie enthaltende pharmacologische Zusammensetzungen
YU43001A (sh) Supstituisani biciklični derivati korisni kao sredstva protiv kancera
IL128524A0 (en) Ether muscarinic antagonists
HK1043590A1 (zh) 毒蕈碱性拮抗物
HUT59410A (en) Process for producing 1-methyl carbapenem derivatives and pharmaceutical compositions comprising same as active ingredient
IL110060A (en) 5-Amino-8- methyl-7-pyrrolidinylquinoline 3-carboxylic acid derivatives their preparation and pharmaceutical compositions containing them
DE60105610D1 (en) Pyrazinonderivate
IL125982A0 (en) 2-(arylphenyl) amino-imidazoline derivatives
CA2326076A1 (en) Novel macrolides
EP0397511A3 (en) Novel cephalosporin compounds and processes for preparation thereof
HUT50327A (en) Process for producing 2-square brackets open /piperidin-4-yl/-methyl square brackets closed-1,2,3,4-tetrahydro-isoquinoline derivatives and pharmaceutical compositions comprising same
HK95092A (en) 2-substituted n,n-di-trimethoxybenzoyl piperazines and pharmaceutical uses thereof
EP0106276B1 (en) 1,4-dihydropyridine derivatives
CA2336380A1 (en) Novel antihistaminic piperidine derivatives and intermediates for the preparation thereof
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
ECSP003642A (es) Antagonistas muscarinicos
RU95120590A (ru) Новые производные эритромицина, метод их получения, фармацевтическая композиция на их основе и промежуточные соединения синтеза
CA2416706A1 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient